跳至主要内容
临床试验/NCT06366854
NCT06366854尚未招募不适用

Hemodynamic Phenotype-Based, Capillary Refill Time-Targeted Resuscitation In Early Septic Shock: The UK ANDROMEDA-SHOCK-2 Randomized Clinical Trial

Guy's and St Thomas' NHS Foundation Trust0 个研究点目标入组 25 人开始时间: 2024年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
25
主要终点
organ support

研究概览

简要总结

The purpose of the trial is to test if a strategy of resuscitation guided by capillary refill time and individualised clinical hemodynamic phenotyping can improve important clinical outcomes within 28 days in septic shock patients compared to usual care.

详细描述

Septic shock is a life-threatening condition caused by a severe infection. It can rapidly cause multi-organ failure and is associated with a high risk of dying. Patients with septic shock need emergency treatment with intravenous fluids, antibiotics and medications to improve blood supply to all organs. However, it is clear that giving too much fluid is harmful and giving not enough fluid can make organ failure worse, too. International guidelines exist but there is still a lot of variation in how doctors apply the guideline. Further, it is likely that a "one-size-fits-all" approach does not help all patients.

Previously, the Andromeda-Shock 1 trial showed that resuscitation guided by regular monitoring of skin perfusion was associated with a lower risk of dying than resuscitation guided by regular blood tests. The UK Andromeda-Shock-2 RCT builds on this. The aim is to investigate whether an individualised approach based on monitoring of skin perfusion combined with individualised treatment of the blood pressure and circulation for 6 hours is better for patients with septic shock and reduces the risk of organ failure and dying compared to usual care.

During the study period, the investigators will also take a total of 40ml of blood and 60ml of urine for special kidney tests to evaluate kidney health and recovery of kidney function.

After the study has finished, the investigators plan to share fully anonymised results with the investigators of the international Andromeda Shock 2 trial to get as much information as possible to answer the research question and help patients in future.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consecutive adult patients (≥ 18 years) with septic shock defined by Sepsis-3 consensus criteria. (ie septic shock defined as suspected or confirmed infection, hyperlactatemia and noradrenaline requirement, after a fluid load of at least 1000mL in 1 hour)

排除标准

  • Any of the following criteria preclude participation to the trial:
  • More than 4 hours since septic shock diagnosis,
  • Surgery or acute renal replacement therapy anticipated to start during the 6h intervention period
  • Active bleeding,
  • Child B-C Cirrhosis
  • Underlying disease process with a life expectancy <90 days
  • Attending clinician deems aggressive resuscitation unsuitable
  • Refractory shock (high risk of death within 24h)
  • Concomitant severe acute respiratory distress syndrome
  • Capillary refill time cannot be accurately assessed

结局指标

主要结局

organ support

时间窗: 28 days

time to cessation of vital organ support

hospital mortality

时间窗: 28 days

number of patients who died in hospital

length of stay

时间窗: 28 days

length of stay in hospital

次要结局

  • mortality(60 days)
  • length of stay(60 days)
  • vital organ support(28 days)

研究者

申办方类型
Other
责任方
Sponsor

相似试验